Sort
82,697 grants matching “vaccine development”
Using microfluidics to realize patient-specific anti-cancer immunotherapies
$1,080,800Polly Morrell Fordyce · Stanford University · DP1 · FY2025 · CA
Development Of Flow Cytometric Technologies For Immune Assays
$1,080,357Mario Roederer · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Malaria Drug Resistance and Disease Virulence
$1,080,355Thomas E Wellems · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
The Southwest National Primate Research Center
$1,080,295Kenneth Parkhurst Trevett · Texas Biomedical Research Institute · P51 · FY2010 · RR
Epigenetic & Post-Translational Mechanisms of Macrophage Resistance to Mycobacterium tuberculosis During HIV Co-Infection
$1,080,143Thomas R Hawn · University Of Washington · R33 · FY2022 · AI
POLYVALENT VACCINE--PHASE III TRIAL IN STAGE IV MELANOMA
$1,080,112John Wayne Cancer Institute · R01 · FY2001 · CA
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY
$1,080,094Aravinda M De Silva · Univ Of North Carolina Chapel Hill · R01 · FY2019 · AI
High throughput NAPPA-proteoimmunomics and Vibrio cholerae vaccine development
$1,079,893Edward T. Ryan · Massachusetts General Hospital · U01 · FY2010 · AI
Immunopathogenesis of Fungal Infections
$1,079,876Michail Lionakis · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Structure and lineage-based immunogen design scientific research support compone
$1,079,836Stephen C Harrison · Duke University · UM1 · FY2016 · AI
Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells
$1,079,736Shaopeng Wang · Arizona State University-Tempe Campus · R01 · FY2022 · AI
Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells
$1,079,736Shaopeng Wang · Arizona State University-Tempe Campus · R01 · FY2021 · AI
Oral Antiviral Prodrugs for Biodefense Initiative
$1,079,540John M Hilfinger · Tsrl, Inc. · U01 · FY2007 · AI
Immunopathogenesis of Fungal Infections
$1,079,497Michail Lionakis · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer
$1,079,344Kamal V. Kannan · Metaclipse Therapeutics Corporation · R44 · FY2018 · CA
Accelerated molecular probe pipeline
$1,079,340Gerard A Cangelosi · Seattle Biomedical Research Institute · U01 · FY2009 · AI
Vaccines and Therapeutics for Anthrax
$1,079,233Stephen H Leppla · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease
$1,079,215Jay Williams Hooper · Geneva Foundation · R01 · FY2019 · AI
PEDIATRIC AIDS CLINICAL TRIAL UNIT
$1,079,037Univ Of Massachusetts Med Sch Worcester · U01 · FY2005 · AI
Use of Bacteriophages to Prevent, Diagnose, and Treat Diseases
$1,079,030Sankar Adhya · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Impact of Environmental Modifications on Pathogenesis and Immunity of Plasmodium falciparum and P. vivax Malaria
$1,078,945James Walter Kazura · University Of California-Irvine · U19 · FY2023 · AI
Addressing COVID-19 Testing Disparities in Vulnerable Populations Using a Community JITAI (Just in Time Adaptive Intervention) Approach: RADxUP Phase III
$1,078,911Maria Eulalia Fernandez · University Of Texas Hlth Sci Ctr Houston · U01 · FY2023 · TR
Role of inflammation, innate resistance, and immunity in carcinogenesis
$1,078,868Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Project 5: IND-enabling Critical Path Project: GMP Manufacture of a Combination I
$1,078,750Amanda Malone · Oak Crest Institute Of Science · U19 · FY2018 · AI
Laboratory And Preclinical Studies Of Flaviviruses
$1,078,623Stephen Whitehead · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI